NAD+ metabolism: Bioenergetics, signaling and manipulation for therapy

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1864, Issue 12, 2016, Pages 1787-1800

  Yang, Yue ^a   Sauve, Anthony A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

NADH; Nicotinamide adenine dinucleotide; Nicotinamide riboside; Nicotinic acid riboside; Tryptophan; Vitamin B3

Indexed keywords

ENZYME; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NICOTINIC ACID; NUCLEOSIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SIRTUIN 1; TRYPTOPHAN;

AGING; ALZHEIMER DISEASE; BIOENERGY; CARDIOMYOPATHY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA REPAIR SYNDROME; ENERGY YIELD; ENZYME ACTIVATION; FATTY LIVER; GERIATRIC DISORDER; HEARING IMPAIRMENT; HUMAN; INFLAMMATORY DISEASE; LIVER CELL CARCINOMA; MANIPULATIVE MEDICINE; METABOLIC DISORDER; METABOLIC SYNDROME X; METABOLISM; MITOCHONDRIAL BIOGENESIS; NOISE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 84991744838     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2016.06.014     Document Type: Review

References (147)

1. [1] Rajakumar, K., Pellagra in the United States: a historical perspective. South. Med. J., 93, 2000.
2. [2] Hegyi, J., Schwartz, R.A., Hegyi, V., Pellagra: dermatitis, dementia, and diarrhea. Int. J. Dermatol. 43 (2004), 1–5.
3. [3] Sydenstricker, V.P., The history of pellagra, its recognition as a disorder of nutrition and its conquest. Am. J. Clin. Nutr. 6 (1958), 409–414.
4. [4] Morabia, A., Joseph Goldberger's research on the prevention of pellagra. J. R. Soc. Med. 101 (2008), 566–568.
5. [5] Goldberger, J., The etiology of pellagra: the significance of certain epidemiological observations with respect thereto. Public Health Rep. 29:1914 (1896-1970), 1683–1686.
6. [6] Goldberger, J., Tanner, W.F., Amino-acid deficiency probably the primary etiological factor in pellagra. Public Health Rep. 37:1922 (1896-1970), 462–486.
7. [7] Goldberger, J., Wheeler, G.A., Lillie, R.D., Rogers, L.M., A further study of butter, fresh beef, and yeast as pellagra preventives, with consideration of the relation of factor p-p of pellagra (and black tongue of dogs) to vitamin B. Public Health Rep. 41:1926 (1896-1970), 297–318.
8. [8] Goldberger, J., Tanner, W.F., A study of the pellagra preventive action of dried beans, casein, dried milk, and brewers’ yeast, and a consideration of the essential preventive factors involved. Public Health Rep. 40 (1925), 54–80.
9. [9] Elvehjem, C.A., Madden, R.J., Strong, F.M., Woolley, D.W., Relation of nicotinic acid and nicotinic acid amide to canine black tongue. J. Am. Chem. Soc. 59 (1937), 1767–1768.
10. [10] Bollet, A.J., Politics and pellagra: the epidemic of pellagra in the U.S. in the early twentieth century. Yale J. Biol. Med. 65 (1992), 211–221.
11. [11] Harden, A., Young, W.J., The alcoholic ferment of yeast-juice. Part II. The conferment of yeast-juice. Proc. R. Soc. Lond. B Biol. Sci. 78 (1906), 369–375.
12. [12] von Euler-Chelpin, H., Fermentation of sugars and fermentative enzymes. Nobel Lecture, the Nobel Foundation, 1929.
13. [13] Warburg, O., Chrisitan, W., Griese, A., Hydrogen-transferring co-enzyme, its composition and mode of functioning. Biochem. Z., 280, 1935.
14. [14] Warburg, O., Christian, W., Pyridine, the hydrogen transfusing component of fermentative enzymes. Helv. Chim. Acta 19 (1936), 79–88.
15. [15] Kornberg, A., The participation of inorganic pyrophosphate in the reversible enzymatic synthesis of diphosphopyridine nucleotide. J. Biol. Chem., 176, 1948, 1475.
16. [16] Preiss, J., Handler, P., Biosynthesis of diphosphopyridine nucleotide. I. Identification of intermediates. J. Biol. Chem. 233 (1958), 488–492.
17. [17] Preiss, J., Handler, P., Biosynthesis of diphosphopyridine nucleotide. II. Enzymatic aspects. J. Biol. Chem. 233 (1958), 493–500.
18. [18] Krebs, H.A., Veech, R.L., Equilibrium relations between pyridine nucleotides and adenine nucleotides and their roles in the regulation of metabolic processes. Adv. Enzyme Regul. 7 (1969), 397–413.
19. [19] Sauve, A.A., NAD + and vitamin B3: from metabolism to therapies. J. Pharmacol. Exp. Ther. 324 (2008), 883–893.
20. [20] Canto, C., Menzies, K.J., Auwerx, J., NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 22 (2015), 31–53.
21. [21] Xu, P., Sauve, A.A., Vitamin B3, the nicotinamide adenine dinucleotides and aging. Mech. Ageing Dev. 131 (2010), 287–298.
22. [22] T.J., Berg, J.M., Stryer, L., Glycolysis is an energy-conversion pathway in many organisms. Biochemistry, vol. Section 16.1, 2001, W H Freeman, New York.
23. [23] Doherty, J.R., Cleveland, J.L., Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest. 123 (2013), 3685–3692.
24. [24] Akram, M., Citric acid cycle and role of its intermediates in metabolism. Cell Biochem. Biophys. 68 (2014), 475–478.
25. [25] Mullen, A.R., Wheaton, W.W., Jin, E.S., Chen, P.H., Sullivan, L.B., Cheng, T., Yang, Y., Linehan, W.M., Chandel, N.S., DeBerardinis, R.J., Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481 (2012), 385–388.
26. [26] Tretter, L., Adam-Vizi, V., Alpha-ketoglutarate dehydrogenase: a target and generator of oxidative stress. Philos. Trans. R. Soc., B 360 (2005), 2335–2345.
27. [27] McLain, A.L., Szweda, P.A., Szweda, L.I., Alpha-ketoglutarate dehydrogenase: a mitochondrial redox sensor. Free Radic. Res. 45 (2011), 29–36.
28. [28] Sazanov, L.A., A giant molecular proton pump: structure and mechanism of respiratory complex I. Nat. Rev. Mol. Cell Biol. 16 (2015), 375–388.
29. [29] Williamson, D.H., Lund, P., Krebs, H.A., The redox state of free nicotinamide-adenine dinucleotide in the cytoplasm and mitochondria of rat liver. Biochem. J. 103 (1967), 514–527.
30. [30] Veech, R.L., Guynn, R., Veloso, D., The time-course of the effects of ethanol on the redox and phosphorylation states of rat liver. Biochem. J. 127 (1972), 387–397.
31. [31] Ying, W., Alano, C.C., Garnier, P., Swanson, R.A., NAD + as a metabolic link between DNA damage and cell death. J. Neurosci. Res. 79 (2005), 216–223.
32. [32] Yang, H., Yang, T., Baur, J.A., Perez, E., Matsui, T., Carmona, J.J., Lamming, D.W., Souza-Pinto, N.C., Bohr, V.A., Rosenzweig, A., de Cabo, R., Sauve, A.A., Sinclair, D.A., Nutrient-sensitive mitochondrial NAD + levels dictate cell survival. Cell 130 (2007), 1095–1107.
33. [33] Pittelli, M., Formentini, L., Faraco, G., Lapucci, A., Rapizzi, E., Cialdai, F., Romano, G., Moneti, G., Moroni, F., Chiarugi, A., Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool. J. Biol. Chem. 285 (2010), 34106–34114.
34. [34] Zhang, T., Berrocal, J.G., Frizzell, K.M., Gamble, M.J., DuMond, M.E., Krishnakumar, R., Yang, T., Sauve, A.A., Kraus, W.L., Enzymes in the NAD + salvage pathway regulate SIRT1 activity at target gene promoters. J. Biol. Chem. 284 (2009), 20408–20417.
35. [35] Zhang, T., Kraus, W.L., SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions. Biochim. Biophys. Acta 1804 (2010), 1666–1675.
36. [36] Canto, C., Auwerx, J., Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)?. Pharmacol. Rev. 64 (2012), 166–187.
37. [37] Gomes, A.P., Price, N.L., Ling, A.J., Moslehi, J.J., Montgomery, M.K., Rajman, L., White, J.P., Teodoro, J.S., Wrann, C.D., Hubbard, B.P., Mercken, E.M., Palmeira, C.M., de Cabo, R., Rolo, A.P., Turner, N., Bell, E.L., Sinclair, D.A., Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155 (2013), 1624–1638.
38. [38] Ying, W., NAD +/NADH and NADP +/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid. Redox Signal. 10 (2008), 179–206.
39. [39] Pollak, N., Dolle, C., Ziegler, M., The power to reduce: pyridine nucleotides–small molecules with a multitude of functions. Biochem. J. 402 (2007), 205–218.
40. [40] Arner, E.S., Holmgren, A., Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267 (2000), 6102–6109.
41. [41] Cejudo, F.J., Ferrandez, J., Cano, B., Puerto-Galan, L., Guinea, M., The function of the NADPH thioredoxin reductase C-2-Cys peroxiredoxin system in plastid redox regulation and signalling. FEBS Lett. 586 (2012), 2974–2980.
42. [42] Tribble, D.L., Jones, D.P., Oxygen dependence of oxidative stress. Rate of NADPH supply for maintaining the GSH pool during hypoxia. Biochem. Pharmacol. 39 (1990), 729–736.
43. [43] Agledal, L., Niere, M., Ziegler, M., The phosphate makes a difference: cellular functions of NADP. Redox Rep. 15 (2010), 2–10.
44. [44] Pandey, A.V., Fluck, C.E., NADPH P450 oxidoreductase: structure, function, and pathology of diseases. Pharmacol. Ther. 138 (2013), 229–254.
45. [45] Segal, A.W., The function of the NADPH oxidase of phagocytes and its relationship to other NOXs in plants, invertebrates, and mammals. Int. J. Biochem. Cell Biol. 40 (2008), 604–618.
46. [46] Kruger, N.J., von Schaewen, A., The oxidative pentose phosphate pathway: structure and organisation. Curr. Opin. Plant Biol. 6 (2003), 236–246.
47. 2 + trigger. Sci. Signal., 1, 2008, re10.
48. [48] Pollak, N., Niere, M., Ziegler, M., NAD kinase levels control the NADPH concentration in human cells. J. Biol. Chem. 282 (2007), 33562–33571.
49. [49] Williams, M.B., Jones, H.P., Calmodulin-dependent NAD kinase of human neutrophils. Arch. Biochem. Biophys. 237 (1985), 80–87.
50. [50] Apps, D.K., Kinetic studies of pigeon liver NAD kinase. Eur. J. Biochem. 5 (1968), 444–450.
51. [51] Zhang, R., MNADK, a novel liver-enriched mitochondrion-localized NAD kinase. Biol. Open 2 (2013), 432–438.
52. [52] Zhang, R., MNADK, a long-awaited human mitochondrion-localized NAD kinase. J. Cell. Physiol. 230 (2015), 1697–1701.
53. [53] Ohashi, K., Kawai, S., Murata, K., Identification and characterization of a human mitochondrial NAD kinase. Nat. Commun., 3, 2012, 1248.
54. [54] Someya, S., Yu, W., Hallows, W.C., Xu, J., Vann, J.M., Leeuwenburgh, C., Tanokura, M., Denu, J.M., Prolla, T.A., Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 143 (2010), 802–812.
55. [55] Chambon, P., Weill, J.D., Mandel, P., Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem. Biophys. Res. Commun. 11 (1963), 39–43.
56. [56] Chambon, P., Weill, J.D., Doly, J., Strosser, M.T., Mandel, P., On formation of a novel adenylic compound by enzymatic extracts of liver nuclei. Biochem. Biophys. Res. Commun., 25, 1966, 638 (-&.).
57. [57] Collier, R.J., Pappenheimer, A.M. Jr., Studies on the mode of action of diphtheria toxin. II. Effect of toxin on amino acid incorporation in cell-free systems. J. Exp. Med. 120 (1964), 1019–1039.
58. [58] Honjo, T., Nishizuka, Y., Hayaishi, O., Diphtheria toxin-dependent adenosine diphosphate ribosylation of aminoacyl transferase II and inhibition of protein synthesis. J. Biol. Chem. 243 (1968), 3553–3555.
59. [59] Hassa, P.O., Haenni, S.S., Elser, M., Hottiger, M.O., Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?. Microbiol. Mol. Biol. Rev. 70 (2006), 789–829.
60. [60] Otto, H., Reche, P.A., Bazan, F., Dittmar, K., Haag, F., Koch-Nolte, F., In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs). BMC Genomics, 6, 2005, 139.
61. [61] Vyas, S., Matic, I., Uchima, L., Rood, J., Zaja, R., Hay, R.T., Ahel, I., Chang, P., Family-wide analysis of poly(ADP-ribose) polymerase activity. Nat. Commun., 5, 2014.
62. [62] Blander, G., Guarente, L., The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 73 (2004), 417–435.
63. [63] Yang, T., Sauve, A.A., NAD metabolism and sirtuins: metabolic regulation of protein deacetylation in stress and toxicity. AAPS J. 8 (2006), E632–E643.
64. [64] Sauve, A.A., Sirtuin chemical mechanisms. Biochim. Biophys. Acta 1804 (2010), 1591–1603.
65. [65] Cen, Y., Youn, D.Y., Sauve, A.A., Advances in characterization of human sirtuin isoforms: chemistries, targets and therapeutic applications. Curr. Med. Chem. 18 (2011), 1919–1935.
66. [66] Barbosa, M.T., Soares, S.M., Novak, C.M., Sinclair, D., Levine, J.A., Aksoy, P., Chini, E.N., The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet-induced obesity. FASEB J. 21 (2007), 3629–3639.
67. [67] Bai, P., Canto, C., Oudart, H., Brunyanszki, A., Cen, Y., Thomas, C., Yamamoto, H., Huber, A., Kiss, B., Houtkooper, R.H., Schoonjans, K., Schreiber, V., Sauve, A.A., Menissier-de Murcia, J., Auwerx, J., PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 13 (2011), 461–468.
68. [68] Cerutti, R., Pirinen, E., Lamperti, C., Marchet, S., Sauve, A.A., Li, W., Leoni, V., Schon, E.A., Dantzer, F., Auwerx, J., Viscomi, C., Zeviani, M., NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab. 19 (2014), 1042–1049.
69. [69] Koltai, E., Szabo, Z., Atalay, M., Boldogh, I., Naito, H., Goto, S., Nyakas, C., Radak, Z., Exercise alters SIRT1, SIRT6, NAD and NAMPT levels in skeletal muscle of aged rats. Mech. Ageing Dev. 131 (2010), 21–28.
70. [70] Qin, W., Yang, T., Ho, L., Zhao, Z., Wang, J., Chen, L., Zhao, W., Thiyagarajan, M., MacGrogan, D., Rodgers, J.T., Puigserver, P., Sadoshima, J., Deng, H., Pedrini, S., Gandy, S., Sauve, A.A., Pasinetti, G.M., Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J. Biol. Chem. 281 (2006), 21745–21754.
71. [71] Canto, C., Sauve, A.A., Bai, P., Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes. Mol. Aspects Med. 34 (2013), 1168–1201.
72. [72] Ijichi, H., Ichiyama, A., Hayaishi, O., Studies on the biosynthesis of nicotinamide adenine dinucleotide. 3. Comparative in vivo studies on nicotinic acid, nicotinamide, and quinolinic acid as precursors of nicotinamide adenine dinucleotide. J. Biol. Chem. 241 (1966), 3701–3707.
73. [73] Jackson, T.M., Rawling, J.M., Roebuck, B.D., Kirkland, J.B., Large supplements of nicotinic acid and nicotinamide increase tissue NAD + and poly(ADP-ribose) levels but do not affect diethylnitrosamine-induced altered hepatic foci in Fischer-344 rats. J. Nutr. 125 (1995), 1455–1461.
74. [74] Terakata, M., Fukuwatari, T., Kadota, E., Sano, M., Kanai, M., Nakamura, T., Funakoshi, H., Shibata, K., The niacin required for optimum growth can be synthesized from L-tryptophan in growing mice lacking tryptophan-2,3-dioxygenase. J. Nutr. 143 (2013), 1046–1051.
75. [75] Moffett, J.R., Namboodiri, M.A., Tryptophan and the immune response. Immunol. Cell Biol. 81 (2003), 247–265.
76. [76] Gal, E.M., Sherman, A.D., L-kynurenine: its synthesis and possible regulatory function in brain. Neurochem. Res. 5 (1980), 223–239.
77. [77] Leklem, J.E., Quantitative aspects of tryptophan metabolism in humans and other species: a review. Am. J. Clin. Nutr. 24 (1971), 659–672.
78. [78] Oxenkrug, G.F., Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later. Isr. J. Psychiatry Relat. Sci. 47 (2010), 56–63.
79. [79] O.B.V. Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, and Choline, Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. 1998, National Academies Press (US), Washington (DC).
80. [80] Salter, M., Beams, R.M., Critchley, M.A., Hodson, H.F., Iyer, R., Knowles, R.G., Madge, D.J., Pogson, C.I., Effects of tryptophan 2,3-dioxygenase inhibitors in the rat. Adv. Exp. Med. Biol. 294 (1991), 281–288.
81. [81] Salter, M., Pogson, C.I., The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes. Biochem. J. 229 (1985), 499–504.
82. [82] Rubin, R.T., Adrenal cortical activity changes in manic-depressive illness. Influence on intermediary metabolism of tryptophan. Arch. Gen. Psychiatry 17 (1967), 671–679.
83. [83] Guillemin, G.J., Smythe, G., Takikawa, O., Brew, B.J., Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49 (2005), 15–23.
84. [84] Guillemin, G.J., Smith, D.G., Smythe, G.A., Armati, P.J., Brew, B.J., Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv. Exp. Med. Biol. 527 (2003), 105–112.
85. [85] Fujigaki, S., Saito, K., Sekikawa, K., Tone, S., Takikawa, O., Fujii, H., Wada, H., Noma, A., Seishima, M., Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur. J. Immunol. 31 (2001), 2313–2318.
86. [86] Chen, Y., Guillemin, G.J., Kynurenine pathway metabolites in humans: disease and healthy states. Int. J. Tryptophan Res. 2 (2009), 1–19.
87. [87] Vecsei, L., Szalardy, L., Fulop, F., Toldi, J., Kynurenines in the CNS: recent advances and new questions. Nat. Rev. Drug Discov. 12 (2013), 64–82.
88. [88] Okuno, E., Schwarcz, R., Purification of quinolinic acid phosphoribosyltransferase from rat liver and brain. Biochim. Biophys. Acta 841 (1985), 112–119.
89. [89] Ikeda, M., Tsuji, H., Nakamura, S., Ichiyama, A., Nishizuka, Y., Hayaishi, O., Studies on the biosynthesis of nicotinamide adenine dinucleotide. II. A role of picolinic carboxylase in the biosynthesis of nicotinamide adenine dinucleotide from tryptophan in mammals. J. Biol. Chem. 240 (1965), 1395–1401.
90. [90] Moehn, S., Pencharz, P.B., Ball, R.O., Lessons learned regarding symptoms of tryptophan deficiency and excess from animal requirement studies. J. Nutr. 142 (2012), 2231 s–2235 s.
91. [91] Fukuwatari, T., Shibata, K., Effect of nicotinamide administration on the tryptophan–nicotinamide pathway in humans. Int. J. Vitam. Nutr. Res. 77 (2007), 255–262.
92. [92] Kimura, T., Bier, D.M., Taylor, C.L., Summary of workshop discussions on establishing upper limits for amino acids with specific attention to available data for the essential amino acids leucine and tryptophan. J. Nutr. 142 (2012), 2245 s–2248 s.
93. [93] Schwarcz, R., Okuno, E., White, R.J., Bird, E.D., Whetsell, W.O. Jr., 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims. Proc. Natl. Acad. Sci. U. S. A. 85 (1988), 4079–4081.
94. [94] Schwarcz, R., Speciale, C., Okuno, E., French, E.D., Kohler, C., Quinolinic acid: a pathogen in seizure disorders?. Adv. Exp. Med. Biol. 203 (1986), 697–707.
95. [95] Lapin, I.P., Mutovkina, L.G., Ryzov, I.V., Mirzaev, S., Anxiogenic activity of quinolinic acid and kynurenine in the social interaction test in mice. J. Psychopharmacol. 10 (1996), 246–249.
96. [96] Lapin, I.P., Neurokynurenines (NEKY) as common neurochemical links of stress and anxiety. Adv. Exp. Med. Biol. 527 (2003), 121–125.
97. [97] French, J.B., Cen, Y., Vrablik, T.L., Xu, P., Allen, E., Hanna-Rose, W., Sauve, A.A., Characterization of nicotinamidases: steady state kinetic parameters, classwide inhibition by nicotinaldehydes, and catalytic mechanism. Biochemistry 49 (2010), 10421–10439.
98. [98] Preiss, J., Handler, P., Enzymatic synthesis of nicotinamide mononucleotide. J. Biol. Chem. 225 (1957), 759–770.
99. [99] Zhu, X.H., Lu, M., Lee, B.Y., Ugurbil, K., Chen, W., In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 2876–2881.
100. [100] Burgos, E.S., Schramm, V.L., Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase. Biochemistry 47 (2008), 11086–11096.
101. [101] Burgos, E.S., Vetticatt, M.J., Schramm, V.L., Recycling nicotinamide. The transition-state structure of human nicotinamide phosphoribosyltransferase. J. Am. Chem. Soc. 135 (2013), 3485–3493.
102. [102] Hasmann, M., Schemainda, I., FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63 (2003), 7436–7442.
103. [103] Montecucco, F., Bauer, I., Braunersreuther, V., Bruzzone, S., Akhmedov, A., Luscher, T.F., Speer, T., Poggi, A., Mannino, E., Pelli, G., Galan, K., Bertolotto, M., Lenglet, S., Garuti, A., Montessuit, C., Lerch, R., Pellieux, C., Vuilleumier, N., Dallegri, F., Mage, J., Sebastian, C., Mostoslavsky, R., Gayet-Ageron, A., Patrone, F., Mach, F., Nencioni, A., Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxid. Redox Signal. 18 (2013), 630–641.
104. [104] Brandauer, J., Vienberg, S.G., Andersen, M.A., Ringholm, S., Risis, S., Larsen, P.S., Kristensen, J.M., Frosig, C., Leick, L., Fentz, J., Jorgensen, S., Kiens, B., Wojtaszewski, J.F., Richter, E.A., Zierath, J.R., Goodyear, L.J., Pilegaard, H., Treebak, J.T., AMP-activated protein kinase regulates nicotinamide phosphoribosyl transferase expression in skeletal muscle. J. Physiol. 591 (2013), 5207–5220.
105. [105] Bender, D.A., Tryptophan and niacin nutrition–is there a problem?. Adv. Exp. Med. Biol. 398 (1996), 565–569.
106. [106] van Roermund, C.W., Elgersma, Y., Singh, N., Wanders, R.J., Tabak, H.F., The membrane of peroxisomes in Saccharomyces cerevisiae is impermeable to NAD(H) and acetyl-CoA under in vivo conditions. EMBO J. 14 (1995), 3480–3486.
107. [107] Bieganowski, P., Brenner, C., Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss–Handler independent route to NAD + in fungi and humans. Cell 117 (2004), 495–502.
108. [108] Tempel, W., Rabeh, W.M., Bogan, K.L., Belenky, P., Wojcik, M., Seidle, H.F., Nedyalkova, L., Yang, T., Sauve, A.A., Park, H.W., Brenner, C., Nicotinamide riboside kinase structures reveal new pathways to NAD +. PLoS Biol., 5, 2007, e263.
109. [109] Dolle, C., Ziegler, M., Application of a coupled enzyme assay to characterize nicotinamide riboside kinases. Anal. Biochem. 385 (2009), 377–379.
110. [110] Yang, T., Chan, N.Y., Sauve, A.A., Syntheses of nicotinamide riboside and derivatives: effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells. J. Med. Chem. 50 (2007), 6458–6461.
111. [111] Belenky, P.A., Moga, T.G., Brenner, C., Saccharomyces cerevisiae YOR071C encodes the high affinity nicotinamide riboside transporter Nrt1. J. Biol. Chem. 283 (2008), 8075–8079.
112. [112] Damaraju, V.L., Visser, F., Zhang, J., Mowles, D., Ng, A.M., Young, J.D., Jayaram, H.N., Cass, C.E., Role of human nucleoside transporters in the cellular uptake of two inhibitors of IMP dehydrogenase, tiazofurin and benzamide riboside. Mol. Pharmacol. 67 (2005), 273–279.
113. [113] Kulikova, V., Shabalin, K., Nerinovski, K., Dolle, C., Niere, M., Yakimov, A., Redpath, P., Khodorkovskiy, M., Migaud, M.E., Ziegler, M., Nikiforov, A., Generation, release, and uptake of the NAD precursor nicotinic acid riboside by human cells. J. Biol. Chem. 290 (2015), 27124–27137.
114. [114] Rowen, J.W., Kornberg, A., The phosphorolysis of nicotinamide riboside. J. Biol. Chem. 193 (1951), 497–507.
115. [115] Boden, W.E., Sidhu, M.S., Toth, P.P., The therapeutic role of niacin in dyslipidemia management. J. Cardiovasc. Pharmacol. Ther. 19 (2014), 141–158.
116. [116] Belenky, P., Racette, F.G., Bogan, K.L., McClure, J.M., Smith, J.S., Brenner, C., Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD +. Cell 129 (2007), 473–484.
117. [117] Song, J., Ke, S.F., Zhou, C.C., Zhang, S.L., Guan, Y.F., Xu, T.Y., Sheng, C.Q., Wang, P., Miao, C.Y., Nicotinamide phosphoribosyltransferase is required for the calorie restriction-mediated improvements in oxidative stress, mitochondrial biogenesis, and metabolic adaptation. J. Gerontol. A Biol. Sci. Med. Sci. 69 (2014), 44–57.
118. [118] Rappou, E., Jukarainen, S., Rinnankoski-Tuikka, R., Kaye, S., Heinonen, S., Hakkarainen, A., Lundbom, J., Lundbom, N., Saunavaara, V., Rissanen, A., Virtanen, K.A., Pirinen, E., Pietilainen, K.H., Weight loss is associated with increased NAD/SIRT1 expression but reduced PARP activity in white adipose tissue. J. Clin. Endocrinol. Metab., 2016 (jc20153054).
119. [119] Canto, C., Houtkooper, R.H., Pirinen, E., Youn, D.Y., Oosterveer, M.H., Cen, Y., Fernandez-Marcos, P.J., Yamamoto, H., Andreux, P.A., Cettour-Rose, P., Gademann, K., Rinsch, C., Schoonjans, K., Sauve, A.A., Auwerx, J., The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 15 (2012), 838–847.
120. [120] Houtkooper, R.H., Auwerx, J., Exploring the therapeutic space around NAD +. J. Cell Biol. 199 (2012), 205–209.
121. [121] Jeninga, E.H., Schoonjans, K., Auwerx, J., Reversible acetylation of PGC-1: connecting energy sensors and effectors to guarantee metabolic flexibility. Oncogene 29 (2010), 4617–4624.
122. [122] Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., Geny, B., Laakso, M., Puigserver, P., Auwerx, J., Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127 (2006), 1109–1122.
123. [123] Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., Prabhu, V.V., Allard, J.S., Lopez-Lluch, G., Lewis, K., Pistell, P.J., Poosala, S., Becker, K.G., Boss, O., Gwinn, D., Wang, M., Ramaswamy, S., Fishbein, K.W., Spencer, R.G., Lakatta, E.G., Le Couteur, D., Shaw, R.J., Navas, P., Puigserver, P., Ingram, D.K., de Cabo, R., Sinclair, D.A., Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444 (2006), 337–342.
124. [124] Dasgupta, B., Milbrandt, J., Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 7217–7222.
125. [125] Park, S.J., Ahmad, F., Philp, A., Baar, K., Williams, T., Luo, H., Ke, H., Rehmann, H., Taussig, R., Brown, A.L., Kim, M.K., Beaven, M.A., Burgin, A.B., Manganiello, V., Chung, J.H., Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148 (2012), 421–433.
126. [126] Pirinen, E., Canto, C., Jo, Y.S., Morato, L., Zhang, H., Menzies, K.J., Williams, E.G., Mouchiroud, L., Moullan, N., Hagberg, C., Li, W., Timmers, S., Imhof, R., Verbeek, J., Pujol, A., van Loon, B., Viscomi, C., Zeviani, M., Schrauwen, P., Sauve, A.A., Schoonjans, K., Auwerx, J., Pharmacological inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab. 19 (2014), 1034–1041.
127. [127] Khan, N.A., Auranen, M., Paetau, I., Pirinen, E., Euro, L., Forsstrom, S., Pasila, L., Velagapudi, V., Carroll, C.J., Auwerx, J., Suomalainen, A., Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO Mol. Med. 6 (2014), 721–731.
128. [128] Qiu, X., Brown, K., Hirschey, M.D., Verdin, E., Chen, D., Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab. 12 (2010), 662–667.
129. [129] Tao, R., Coleman, M.C., Pennington, D., Ozden, O., Park, S.-H., Jiang, H., Kim, H.-S., Flynn, C.R., Hill, S., McDonald, W.H., Olivier, A.K., Spitz, D.R., Gius, D., Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol. Cell 40 (2010), 893–904.
130. [130] Mohrin, M., Shin, J., Liu, Y., Brown, K., Luo, H., Xi, Y., Haynes, C.M., Chen, D., Stem cell aging. A mitochondrial UPR-mediated metabolic checkpoint regulates hematopoietic stem cell aging. Science 347 (2015), 1374–1377.
131. [131] Lightowlers, R.N., Chrzanowska-Lightowlers, Z.M., Salvaging hope: is increasing NAD(+) a key to treating mitochondrial myopathy?. EMBO Mol. Med. 6 (2014), 705–707.
132. [132] Gitiaux, C., Blin-Rochemaure, N., Hully, M., Echaniz-Laguna, A., Calmels, N., Bahi-Buisson, N., Desguerre, I., Dabaj, I., Wehbi, S., Quijano-Roy, S., Laugel, V., Progressive demyelinating neuropathy correlates with clinical severity in Cockayne syndrome. Clin. Neurophysiol. 126 (2015), 1435–1439.
133. [133] Moriel-Carretero, M., Herrera-Moyano, E., Aguilera, A., A unified model for the molecular basis of xeroderma pigmentosum-Cockayne syndrome. Rare Dis., 3, 2015, e1079362.
134. [134] Scheibye-Knudsen, M., Mitchell, S.J., Fang, E.F., Iyama, T., Ward, T., Wang, J., Dunn, C.A., Singh, N., Veith, S., Hasan-Olive, M.M., Mangerich, A., Wilson, M.A., Mattson, M.P., Bergersen, L.H., Cogger, V.C., Warren, A., Le Couteur, D.G., Moaddel, R., Wilson, D.M. 3rd, Croteau, D.L., de Cabo, R., Bohr, V.A., A high-fat diet and NAD(+) activate Sirt1 to rescue premature aging in Cockayne syndrome. Cell Metab. 20 (2014), 840–855.
135. [135] Gong, B., Pan, Y., Vempati, P., Zhao, W., Knable, L., Ho, L., Wang, J., Sastre, M., Ono, K., Sauve, A.A., Pasinetti, G.M., Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol. Aging 34 (2013), 1581–1588.
136. [136] Gariani, K., Menzies, K.J., Ryu, D., Wegner, C.J., Wang, X., Ropelle, E.R., Moullan, N., Zhang, H., Perino, A., Lemos, V., Kim, B., Park, Y.K., Piersigilli, A., Pham, T.X., Yang, Y., Ku, C.S., Koo, S.I., Fomitchova, A., Canto, C., Schoonjans, K., Sauve, A.A., Lee, J.Y., Auwerx, J., Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice. Hepatology 63 (2016), 1190–1204.
137. [137] Shin, J., He, M., Liu, Y., Paredes, S., Villanova, L., Brown, K., Qiu, X., Nabavi, N., Mohrin, M., Wojnoonski, K., Li, P., Cheng, H.L., Murphy, Andrew J., Valenzuela, David M., Luo, H., Kapahi, P., Krauss, R., Mostoslavsky, R., Yancopoulos, George D., Alt, Frederick W., Chua, Katrin F., Chen, D., SIRT7 represses Myc activity to suppress er stress and prevent fatty liver disease. Cell Rep., 5, 2013, 1479.
138. [138] Ryu, D., Jo, Young S., Lo Sasso, G., Stein, S., Zhang, H., Perino, A., Lee, Jung U., Zeviani, M., Romand, R., Hottiger, Michael O., Schoonjans, K., Auwerx, J., A SIRT7-dependent acetylation switch of GABPbeta1 controls mitochondrial function. Cell Metab. 20 (2014), 856–869.
139. [139] Tummala, K.S., Gomes, A.L., Yilmaz, M., Grana, O., Bakiri, L., Ruppen, I., Ximenez-Embun, P., Sheshappanavar, V., Rodriguez-Justo, M., Pisano, D.G., Wagner, E.F., Djouder, N., Inhibition of de novo NAD(+) synthesis by oncogenic URI causes liver tumorigenesis through DNA damage. Cancer Cell 26 (2014), 826–839.
140. [140] Vandanmagsar, B., Youm, Y.H., Ravussin, A., Galgani, J.E., Stadler, K., Mynatt, R.L., Ravussin, E., Stephens, J.M., Dixit, V.D., The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17 (2011), 179–188.
141. [141] Anders, H.J., Schaefer, L., Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis. J. Am. Soc. Nephrol. 25 (2014), 1387–1400.
142. [142] Traba, J., Kwarteng-Siaw, M., Okoli, T.C., Li, J., Huffstutler, R.D., Bray, A., Waclawiw, M.A., Han, K., Pelletier, M., Sauve, A.A., Siegel, R.M., Sack, M.N., Fasting and refeeding differentially regulate NLRP3 inflammasome activation in human subjects. J. Clin. Invest. 125 (2015), 4592–4600.
143. [143] Xu, W., Barrientos, T., Mao, L., Rockman, H.A., Sauve, A.A., Andrews, N.C., Lethal cardiomyopathy in mice lacking transferrin receptor in the heart. Cell Rep. 13 (2015), 533–545.
144. [144] Brown, K.D., Maqsood, S., Huang, J.Y., Pan, Y., Harkcom, W., Li, W., Sauve, A., Verdin, E., Jaffrey, S.R., Activation of SIRT3 by the NAD(+) precursor nicotinamide riboside protects from noise-induced hearing loss. Cell Metab. 20 (2014), 1059–1068.
145. [145] Verdin, E., NAD(+) in aging, metabolism, and neurodegeneration. Science 350 (2015), 1208–1213.
146. [146] Brown, K., Xie, S., Qiu, X., Mohrin, M., Shin, J., Liu, Y., Zhang, D., Scadden, D.T., Chen, D., SIRT3 reverses aging-associated degeneration. Cell Rep. 3 (2013), 319–327.
147. [147] Harman, D., Origin and evolution of the free radical theory of aging: a brief personal history, 1954-2009. Biogerontology 10 (2009), 773–781.